slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 6,691-6,720
Pages 395
Rows per page 30
Slide function
6,691-6,720 of 11,828
37
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
38
Includes survival curves, median survival comparison, and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
40
Includes waterfall chart for best percentage change and line charts for longitudinal tumor size tracking against PD/PR thresholds.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
48
Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
13
The slide presents clinical trial data (STAI-G scores) over 24 weeks, highlighting significant symptom reduction and safety profile.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Traction1 hit
24
The chart shows improvement in social anxiety at 1 month and 6 months, indicating durability of effect.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
06
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
07
The slide uses a 'Target vs Status' framework to demonstrate progress.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
09
The slide presents two line charts: one comparing BGM vs Invasive CGM, and one showing raw sugarBEAT data.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
32
The slide uses two line charts to visualize clinical trial data with p-values and delta LSM values.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
14
The slide uses a grid of metrics to present financial performance.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · FinancialsLoop · Golden Circle1 hit
10
Includes a legend for extraordinary items and a disclaimer regarding non-GAAP adjustments for FY 2022.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
The slide uses a Venn-like circular layout to present two key capital return metrics alongside qualitative operational targets.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
The slide uses a grid of 8 metric cards, each with an icon, a headline number, and a descriptive sub-text.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
16
The chart highlights the acquisition of Crestmark in 2018.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
11
The slide uses a comparison table to validate the market potential of the radiopharmaceutical space by highlighting a competitor's success.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Why Now1 hit
18
Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
19
The chart tracks patient follow-up in weeks, with markers indicating dose, dose reduction, and clinical response (Partial Response, Progressive Disease, Stable Disease).RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
24
Includes a visual case study with PET scan images showing tumor reduction.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
25
The chart shows tumor growth over 57 days across four treatment groups, with the combination therapy (green line) demonstrating the most effective tumor suppression.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
33
Comparison of 225Ac vs 177Lu efficacy at significantly different dose levels.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
34
Includes clinical imaging examples for two patients.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
35
The slide uses a longitudinal imaging sequence to demonstrate drug efficacy/retention.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
37
The slide lists 24 investor logos/names.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
06
The slide uses a bar chart to represent asset growth over time, with logos marking the founding years of subsidiaries.VinFast | Investor Presentation Deck | 33 slides · VinFast
Pitch deck Investor relations 1 hit